| |
See how this AI-powered tool provided the sponsor a real-time competitive landscape evaluation for Immuno-oncology therapies with valuable insights for enhanced decision-making. Read the case study.
|
|
|
Join us at the Fierce Medical Affairs Strategic Summit West and hear industry-leading speakers from Amgen, Abbott, Bayer, Gilead, Janssen, Otsuka, Daiichi Sankyo, and many more. Register now with early bird rates and save $200.
|
|
| By Annalee Armstrong Scientists have long known that cancer cells typically have extra chromosomes, but what exactly was the extra genetic material doing? New research from a team at Yale University has finally provided an answer. |
|
|
|
By Angus Liu After a major phase 2 win that stirred up much excitement within the oncology community, Merck has officially formulated a pivotal trial plan for its Moderna-partnered mRNA cancer vaccine mRNA-4157. |
By Kevin Dunleavy Two cases of suicidal thoughts and one case of self-harm from users in Iceland of Novo Nordisk’s diabetes and obesity drugs have prompted the European Medicines Agency (EMA) to review the blockbuster products. The regulator will examine Novo’s treatments Ozempic and Saxenda to determine if there was a causal relationship between their use and the adverse events. |
By Zoey Becker A total of 12 severe adverse events were reported among the 40 patients enrolled in the phase 2 trial, 11 of which ADC says were not related to the treatment. The study was assessing the drug in certain patients with previously untreated diffuse large B-cell lymphoma. |
By James Waldron Novartis may have insisted earlier this year that it hadn’t given up on anti-TIGIT checkpoint inhibitors, but, now, the Swiss Big Pharma seems to have had a change of heart. |
By Ben Adams Novartis is in hot water with the U.K.’s drug marketing rule maker the PMCPA after it was found to have breached three of its rules, including its most serious: Clause 2. |
By Gabrielle Masson Eli Lilly’s Prevail Therapeutics has changed up a licensing agreement with gene therapy biotech Precision Therapeutics, dropping the biobucks value and seeking a bigger share of pre-clinical duties. |
By Fraiser Kansteiner Samsung Biologics said in a Monday regulatory filing that it’s inked a $390.9 million deal to help crank out Novartis drugs. The latest production pact builds on an earlier tie-up worth $81 million. |
By Andrea Park There’s something fishy about Coloplast’s latest megadeal—literally. The Danish medtech announced plans on Friday to acquire Kerecis, which uses fish skin as the basis of its wound care products for humans. |
By Angus Liu Canada has canceled some COVID-19 vaccine deliveries from Novavax and will pay $350 million to fully compensate the company for those unused doses. The survival of the Maryland-based company now depends on the successful delivery of an updated COVID shot this fall. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss the state of digital phenotyping, plus the vaccine patent lawsuits, the smallest insulin pump, and the rest of the week's headlines. |
|
|---|
|
|
| ResearchThe right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperBest practices from biopharma clinical studies for medical device manufacturers around the efficient collection and use of data to speed insights into product safety and efficacy Sponsored by: Cognizant |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| WhitepaperShave up to six months off the development timeline of a mAb candidate Sponsored by: Curia Global |
| eBookThis eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookTake a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperModern software development and its impact on addressing clinical trial complexity. Sponsored by: YPrime |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| |
|
